Coherus Oncology, Inc. (CHRS) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $1.79 (+0.85%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 24, 2025 | Ashwani Verma | UBS | $1.05 | -41.3% |
| Dec 5, 2024 | Colleen Kusy | Robert W. Baird | $6.00 | +235.2% |
| Jun 13, 2022 | Ashwani Verma | UBS | $7.00 | +291.1% |
Top Analysts Covering CHRS
CHRS vs Sector & Market
| Metric | CHRS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | — | 2.24 | 2.41 |
| Analyst Count | — | 8 | 18 |
| Target Upside | +236.3% | +1150.0% | +14.9% |
| P/E Ratio | 1.27 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $58M | $84M | $133M | 5 |
| 2027-03-31 | $13M | $24M | $44M | 1 |
| 2027-06-30 | $14M | $26M | $49M | 2 |
| 2027-09-30 | $16M | $30M | $57M | 2 |
| 2027-12-31 | $19M | $35M | $65M | 1 |
| 2028-03-31 | $22M | $42M | $78M | 1 |
| 2028-06-30 | $23M | $44M | $81M | 1 |
| 2028-09-30 | $25M | $47M | $88M | 1 |
| 2028-12-31 | $26M | $49M | $91M | 1 |
| 2029-12-31 | $207M | $261M | $351M | 2 |
| 2030-12-31 | $283M | $357M | $480M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.40 | $-0.96 | $-0.71 | 2 |
| 2027-03-31 | $-0.36 | $-0.17 | $-0.07 | 1 |
| 2027-06-30 | $-0.36 | $-0.17 | $-0.07 | 1 |
| 2027-09-30 | $-0.40 | $-0.19 | $-0.07 | 1 |
| 2027-12-31 | $-0.40 | $-0.19 | $-0.07 | 1 |
| 2028-03-31 | $0.00 | $0.00 | $0.00 | 0 |
| 2028-06-30 | $0.00 | $0.00 | $0.00 | 0 |
| 2028-09-30 | $0.00 | $0.00 | $0.00 | 0 |
| 2028-12-31 | $0.00 | $0.00 | $0.00 | 0 |
| 2029-12-31 | $-0.43 | $-0.30 | $-0.22 | 2 |
| 2030-12-31 | $0.22 | $0.30 | $0.44 | 2 |
Frequently Asked Questions
What is the analyst consensus for CHRS?
The consensus among 0 analysts covering Coherus Oncology, Inc. (CHRS) is — with an average price target of $6.02.
What is the highest price target for CHRS?
The highest price target for CHRS is $7.00, set by Ashwani Verma at UBS on 2022-06-13.
What is the lowest price target for CHRS?
The lowest price target for CHRS is $1.05, set by Ashwani Verma at UBS on 2025-04-24.
How many analysts cover CHRS?
0 analysts have issued ratings for Coherus Oncology, Inc. in the past 12 months.
Is CHRS a buy or sell right now?
Based on 0 analyst ratings, CHRS has a consensus rating of — with a +236.3% upside to the consensus target of $6.02.
What are the earnings estimates for CHRS?
Analysts estimate CHRS will report EPS of $-0.96 for the period ending 2026-12-31, with revenue estimated at $84M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.